IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Robert Falotico, et al. Confirmation No. 7706

Serial No.: 10/813,965 Art Unit: 1628

Filed: March 31, 2004 Examiner: Jennifer M. Kim

For : SOLUTION FORMULATIONS OF SIROLIMUS AND ITS ANALOGS

FOR CAD TREATMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

Pursuant to 37 C.F.R. §1.56 and in accordance with 37 C.F.R. §81.97-1.98, information relating to the above-identified application is hereby disclosed. Inclusion of information in this statement is not to be construed as an admission that this information is material as that term is defined in 37 C.F.R. \$1.56(b).

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist.

 \square In accordance with §1.97(b), since this Information Disclosure Statement is being filed either within three months of the filing date of the above-identified national application (other than a continued prosecution application under §1.53(d)),

within three months of the date of entry into the national stage of the above identified application as set forth in \$1.491, or before the mailing date of a first Office Action on the merits of the above-identified application, or before the mailing date of a first Office Action after the filing of a request for continued examination under \$1.114, no additional fee is required. In accordance with \$1.129(a), this Information Disclosure Statement is being filed in connection with | the first or | second After Final Submission, therefore: Statement in Accordance with \$1.97(e) (attached); П Please charge Deposit Account No. 10-/ the fee of \$180.00 as set forth in $\S1.17(p)$. In accordance with \$1.97(c), this Information Disclosure Statement is being filed after the period set forth in §1.97(b) above but before the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311, or an action that otherwise closes prosecution and that it is accompanied by one of: Statement in Accordance with §1.97(e) (attached); or Please charge Deposit Account No. 10-0750/ the П fee of \$180.00 as set forth in \$1.17(p).

☐ In accordance with §1.97(d), this Information

Disclosure Statement is being filed after the mailing date of either a Final Action under §1.113 or a Notice of Allowance under §1.311 but before the payment of the Issue Fee.

Applicant(s) hereby petition(s) for consideration of this

Information Disclosure Statement. Included are: Statement in

\$180.00 as set forth in §1.17(p).		
attached E	-	es of each of the references listed on the TTO-1449 are enclosed herewith.
☐ 1449 are ∈	_	es of references listed on the attached Form PTO- \ensuremath{PTO} ded herewith EXCEPT THAT:
		In view of the voluminous nature of references [list as appropriate], and the likelihood that these references are available to the Examiner, copies are not enclosed herewith.
		If any of the foregoing publications are not available to the Examiner, Applicant will endeavor to supply copies at the Examiner's request.
igties Copies of only foreign patent documents and non-patent literature are enclosed in accordance with 37 CFR 1.98 (a)(2).		
KUGI	ZAMA i	s cited to include the year "1990"
NEMECEK is cited to correct the year to read "1989"		
SIDDI	i IUQI	is cited to correct the year to read "1988"
oxtimes There are no listed references which are not in the English language.		
in the Eng		relevance of those listed references which are not language is as follows: